Opportunities Preloader

Please Wait.....

Report

NA Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

Market Report I 2023-04-01 I 126 Pages I Data Bridge Market Research

North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach USD 6,797.66 million by 2030 from USD 7,675.00 million in 2022, growing at a CAGR of 7.2% during the forecast period from 2023 to 2030.
Market Segmentation:
North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Dignosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), and Others), Drugs Type (Branded and Generic), End User (Specialty Clinics, Hospitals, Diagnostic Center, Homecare, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others), Industry Trends and Forecast to 2030.


Overview of North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Dynamics:

Driver
- Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis

Restraint

- Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector

Opportunity

- Increasing prevalence of pancreatic disorders and associated conditions


Market Players:

Some of the key market players operating in the North America exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are listed below:

- EagleBio
- AbbVie.
- Digestive Care, Inc.
- Alcresta Therapeutics, Inc.
- ChiRhoClin
- Laboratory Corporation of America
- Organon group of companies
- Metagenics LLC
- Janssen
- Nestle.
- VIVUS LLC.
- ScheBo Biotech AG
- Abbott.


TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET 15
1.4 LIMITATIONS 17
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 PRODUCT TYPE LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET TESTING TYPE COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 34
4.1 PESTEL ANALYSIS 35
4.2 PORTER ANALYSIS 36
5 INDUSTRY INSIGHTS 37
6 REGULATORY FRAMEWORK 39
7 MARKET OVERVIEW 41
7.1 DRIVERS 43
7.1.1 INCREASING PREVALENCE OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) DUE TO CHRONIC PANCREATITIS AND CYSTIC FIBROSIS 43
7.1.2 RISING TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSIS AND TREATMENT OF EPI 43
7.1.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 44
7.1.4 SEDENTARY LIFESTYLES AND UNHEALTHY DIETS 44
7.2 RESTRAINTS 45
7.2.1 STRINGENT REGULATIONS TO HAMPER THE EXOCRINE PANCREATIC INSUFFICIENCY(EPI) THERAPEUTIC AND DIAGNOSTIC SECTOR 45
7.2.2 SIDE EFFECTS AND RELIGIOUS HURDLES ASSOCIATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 45
7.3 OPPORTUNITIES 46
7.3.1 INCREASING PREVALENCE OF PANCREATIC DISORDERS AND ASSOCIATED CONDITION 46
7.3.2 RISING AWARENESS ABOUT THE BENEFITS OF EARLY DIAGNOSIS AND TREATMENT OF EPI 46
7.3.3 GROWING DEMAND FOR COMBINATION THERAPIES AND PERSONALIZED MEDICINE 47
7.4 CHALLENGES 48
7.4.1 HIGH COST ASSOCIATED WITH EPI DIAGNOSIS AND TREATMENT 48
7.4.2 LIMITED AVAILABILITY OF EPI THERAPEUTICS AND DIAGNOSTICS 48
8 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY TREATMENT 49
8.1 OVERVIEW 50
8.2 PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) 53
8.2.1 BY ENZYME 53
8.2.1.1 LIPASE 54
8.2.1.2 PROTEASE 54
8.2.1.3 AMYLASE 54
8.2.2 BY ROUTE OF ADMINISTRATION 54
8.2.2.1 ORAL 55
8.2.2.1.1 CAPSULES 55
8.2.2.1.2 TABLETS 55
8.2.2.1.3 POWDER 55
8.2.2.2 INTRAVENOUS 55
8.3 NUTRITIONAL MANAGEMENT 56
8.3.1 VITAMIN D 57
8.3.2 VITAMIN E 57
8.3.3 VITAMIN A 57
8.3.4 VITAMIN K 57
8.3.5 OTHERS 57
9 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSIS 58
9.1 OVERVIEW 59
9.2 PANCREATIC FUNCTION TEST 61
9.2.1 STOOL 62
9.2.1.1 FECAL ELASTASE TEST 63
9.2.1.2 FECAL FAT TEST 63
9.2.2 SECRETIN PANCREATIC FUNCTION TEST 63
9.2.3 BLOOD TESTS 63
9.2.4 C-MIXED TRIGLYCERIDES BREATH TEST 63
9.2.5 FASTING PLASMA GLUCOSE TEST 63
9.3 IMAGING TEST 63
9.3.1 CT SCANNING 65
9.3.2 MAGNETIC RESONANCE IMAGING TESTS (MRI) 65
9.3.3 ENDOSCOPIC RETROGRADE PANCREATOGRAPHY 65
9.3.4 ENDOSCOPIC ULTRA-SONOGRAPHY (EUS) 65
9.3.5 SECRETIN-STIMULATED MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY 65
10 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUG TYPE 66
10.1 OVERVIEW 67
10.2 BRANDED 69
10.2.1 CREON 70
10.2.2 ZENPEP 71
10.2.3 PANCREAZE 71
10.2.4 NUTRIZYM 71
10.2.5 PANCREASE MT 71
10.2.6 PANCREX 71
10.2.7 COTAZYM 71
10.2.8 ULTERSA 71
10.2.9 VIOKACE 71
10.2.10 PERTZYE 71
10.2.11 OTHERS 72
10.3 GENERIC 72
11 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY END USER 73
11.1 OVERVIEW 74
11.2 HOSPITALS 76
11.2.1 PRIVATE 77
11.2.2 PUBLIC 77
11.3 SPECIALTY CLINICS 77
11.4 DIAGNOSTIC CENTER 78
11.5 HOMECARE 79
11.6 RESEARCH AND ACADEMIC INSTITUTES 80
11.7 OTHERS 81
12 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 82
12.1 OVERVIEW 83
12.2 DIRECT TENDER 85
12.3 RETAIL PHARMACY 86
12.4 THIRD PARTY DISTRIBUTORS 87
12.5 OTHERS 88
13 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION 89
13.1 NORTH AMERICA 90
13.1.1 U.S. 94
13.1.2 CANADA 94
13.1.3 MEXICO 94
14 NORTH AMERICA EXOCRINE PANCREATIC INSUFFICIENCY (EPI) THERAPEUTICS AND DIAGNOSTICS MARKET: COMPANY LANDSCAPE 95
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 95
15 SWOT ANALYSIS 96
16 COMPANY PROFILE 97
16.1 ABBVIE INC. 97
16.1.1 COMPANY SNAPSHOT 97
16.1.2 REVENUE ANALYSIS 97
16.1.3 COMPANY SHARE ANALYSIS 98
16.1.4 PRODUCT PORTFOLIO 98
16.1.5 RECENT DEVELOPMENT 98
16.2 ABBOTT 99
16.2.1 COMPANY SNAPSHOT 99
16.2.2 REVENUE ANALYSIS 99
16.2.3 COMPANY SHARE ANALYSIS 100
16.2.4 PRODUCT PORTFOLIO 100
16.2.5 RECENT DEVELOPMENT 100
16.3 NESTLE 101
16.3.1 COMPANY SNAPSHOT 101
16.3.2 REVENUE ANALYSIS 101
16.3.3 COMPANY SHARE ANALYSIS 102
16.3.4 PRODUCT PORTFOLIO 102
16.3.5 RECENT DEVELOPMENTS 102
16.4 LABORATORY CORPORATION OF AMERICA HOLDINGS (2022) 103
16.4.1 COMPANY SNAPSHOT 103
16.4.2 REVENUE ANALYSIS 103
16.4.3 COMPANY SHARE ANALYSIS 104
16.4.4 PRODUCT PORTFOLIO 104
16.4.5 RECENT DEVELOPMENT 104
16.5 JANSSEN NORTH AMERICA SERVICES, LLC 105
16.5.1 COMPANY SNAPSHOT 105
16.5.2 REVENUE ANALYSIS 105
16.5.3 COMPANY SHARE ANALYSIS 106
16.5.4 PRODUCT PORTFOLIO 106
16.5.5 RECENT DEVELOPMENT 106
16.6 ALCRESTA THERAPEUTICS, INC. 107
16.6.1 COMPANY SNAPSHOT 107
16.6.2 COMPANY SHARE ANALYSIS 107
16.6.3 PRODUCT PORTFOLIO 108
16.6.4 RECENT DEVELOPMENT 108
16.7 BIOSERV DIAGNOSTICS GMBH 109
16.7.1 COMPANY SNAPSHOT 109
16.7.2 PRODUCT PORTFOLIO 109
16.7.3 RECENT DEVELOPMENT 109
16.8 CILIAN AG 110
16.8.1 COMPANY SNAPSHOT 110
16.8.2 PRODUCT PORTFOLIO 110
16.8.3 RECENT DEVELOPMENT 110
16.9 CHIRHOCLIN 111
16.9.1 COMPANY SNAPSHOT 111
16.9.2 COMPANY SHARE ANALYSIS 111
16.9.3 PRODUCT PORTFOLIO 112
16.9.4 RECENT DEVELOPMENT 112
16.10 DIGESTIVE CARE, INC. 113
16.10.1 COMPANY SNAPSHOT 113
16.10.2 PRODUCT PORTFOLIO 113
16.10.3 RECENT DEVELOPMENT 113
16.11 EAGLEBIO 114
16.11.1 COMPANY SNAPSHOT 114
16.11.2 PRODUCT PORTFOLIO 114
16.11.3 RECENT DEVELOPMENT 114
16.12 METAGENICS LLC 115
16.12.1 COMPANY SNAPSHOT 115
16.12.2 PRODUCT PORTFOLIO 115
16.12.3 RECENT DEVELOPMENT 115
16.13 NORDMARK 116
16.13.1 COMPANY SNAPSHOT 116
16.13.2 COMPANY SHARE ANALYSIS 116
16.13.3 PRODUCT PORTFOLIO 117
16.13.4 RECENT DEVELOPMENT 117
16.14 ORGANON GROUP OF COMPANIES. 118
16.14.1 COMPANY SNAPSHOT 118
16.14.2 REVENUE ANALYSIS 118
16.14.3 PRODUCT PORTFOLIO 119
16.14.4 RECENT DEVELOPMENT 119
16.15 SCHEBO BIOTECH AG 120
16.15.1 COMPANY SNAPSHOT 120
16.15.2 PRODUCT PORTFOLIO 120
16.15.3 RECENT DEVELOPMENT 120
16.16 VIVUS LLC 121
16.16.1 COMPANY SNAPSHOT 121
16.16.2 COMPANY SHARE ANALYSIS 121
16.16.3 PRODUCT PORTFOLIO 122
16.16.4 RECENT DEVELOPMENT 122
17 QUESTIONNAIRE 123
18 RELATED REPORTS 126

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE